Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat long-term extension in rapidly progressive ADPKD
2020-004400-34Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of venglustat in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Sanofi. Primary endpoint: Percent change in total kidney volume. Started Dec 2020; status: terminated.
02
Drugs
venglustat
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2020-004400-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004400-34.